{"id":3960,"date":"2026-10-28T09:00:00","date_gmt":"2026-10-28T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3960"},"modified":"2026-10-28T20:49:38","modified_gmt":"2026-10-29T00:49:38","slug":"liger-hn1-meets-survival-and-response-endpoints","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3960","title":{"rendered":"LiGeR HN1 Meets Survival and Response Endpoints"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Genmab<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 interim topline<\/p>\n

Modality<\/strong><\/p>\n

EGFR\/LGR5 bispecific antibody plus anti-PD-1<\/p>\n

Asset<\/strong><\/p>\n

Petosemtamab plus pembrolizumab (LiGeR-HN1)<\/p>\n

Target<\/strong><\/p>\n

EGFR; LGR5; PD-1<\/p>\n

Disease Area<\/strong><\/p>\n

First-line PD-L1-positive recurrent or metastatic head and neck cancer<\/p>\n

Summary<\/h4>\n

Genmab reported on 28 October that first-line petosemtamab plus pembrolizumab met both Phase III LiGeR-HN1 primary endpoints against pembrolizumab alone in PD-L1-positive recurrent or metastatic head-and-neck cancer. Overall-survival HR was 0.50, but absolute survival and detailed safety remain unreleased.<\/p>\n

At the independent first interim analysis, Genmab reported OS HR 0.50 (95% CI 0.37\u20130.67; p<0.0001) and objective-response odds ratio 3.17 (95% CI 2.06\u20134.89; p<0.0001). The global randomized open-label trial assigned patients 1:1. The company said no new safety signal was identified and plans regulatory discussions and a future full presentation. It did not provide median OS, response duration, grade-specific adverse events or quality-of-life outcomes.<\/p>\n

Deep Analysis<\/h4>\n

A randomized survival effect is more persuasive than the earlier single-arm activity, and it makes EGFR\/LGR5 bispecific targeting a plausible first-line competitor. However, pembrolizumab monotherapy is only one relevant comparator; chemoimmunotherapy may be chosen for patients needing rapid tumor control. Eligibility by PD-L1 positivity, HPV balance, subsequent therapies and maturity affect transportability. The active Fc domain and dual binding raise questions about skin toxicity, infusion reactions and normal LGR5-expressing tissue that topline reassurance cannot settle.<\/p>\n

Company and Product Background<\/h4>\n

Petosemtamab is a low-fucose IgG1 bispecific antibody against EGFR and LGR5; pembrolizumab blocks PD-1. Recurrent\/metastatic HNSCC has substantial post-therapy mortality.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> the combination confers meaningful survival benefit in selected PD-L1-positive disease; randomized OS supports it.<\/li>\n
  • Interpretation B:<\/strong> comparator selection or immature follow-up exaggerates real-world displacement; full curves and subsequent-therapy data are missing.<\/li>\n
  • Upgrade<\/strong> with mature absolute OS, tolerability and quality-of-life results. Downgrade<\/strong> with high treatment burden or subgroup heterogeneity. Failure to reproduce benefit against modern chemoimmunotherapy would narrow displacement.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: this is a strong pivotal signal for petosemtamab, while regulatory eligibility and positioning await full data.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: positive within the tested comparison. Confidence in Facts: high for topline. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Genmab reported on 28 October that first-line petosemtamab plus pembrolizumab met both Phase III LiGeR-HN1 primary endpoints against pembrolizumab alone in PD-L1-positive recurrent or metastatic head-and-neck cancer. Overall-survival HR was 0.50, but absolute survival…<\/p>\n","protected":false},"author":1,"featured_media":3973,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[54,721,522,1265,1107],"class_list":["post-3960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-genmab","tag-head-and-neck-cancer","tag-pembrolizumab","tag-petosemtamab","tag-phase-3"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3960"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3960\/revisions"}],"predecessor-version":[{"id":3976,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3960\/revisions\/3976"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3973"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}